Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness
暂无分享,去创建一个
P. Delvenne | R. Hustinx | L. Bettendorff | B. Costanza | J. Bellier | V. Castronovo | M. Thiry | O. Peulen | A. Bellahcène | P. Lovinfosse | M. Herfs | C. Deroanne | G. Rademaker | Raphaël Peiffer | M. Nokin | V. Hennequière | S. Gofflot | L. Brohée | F. Durieux
[1] Christopher Thomas,et al. A Comparison of Dynamic Strength Index between Team-Sport Athletes , 2017, Sports.
[2] C. Tournigand,et al. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro‐intestinal cancers Part 1: GI carcinomas , 2017, Pharmacology & therapeutics.
[3] P. Delvenne,et al. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer , 2017, Oncogene.
[4] Matthew G. Vander Heiden,et al. Understanding the Intersections between Metabolism and Cancer Biology , 2017, Cell.
[5] D. Chan,et al. Mfn1 structures reveal nucleotide-triggered dimerization critical for mitochondrial fusion , 2017, Nature.
[6] C. Lyssiotis,et al. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. , 2017, Cancer cell.
[7] D. Baiwir,et al. Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes , 2016, Oncotarget.
[8] M. Belvin,et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. , 2016, Nature chemical biology.
[9] E. Giannoni,et al. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells , 2016, Oncotarget.
[10] Prashant Mishra,et al. Metabolic regulation of mitochondrial dynamics , 2016, The Journal of cell biology.
[11] S. Hyun,et al. Intratumoral heterogeneity of 18F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[12] P. Delvenne,et al. Myoferlin plays a key role in VEGFA secretion and impacts tumor‐associated angiogenesis in human pancreas cancer , 2016, International journal of cancer.
[13] Gregory McAllister,et al. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy , 2015, Proceedings of the National Academy of Sciences.
[14] E. Giannoni,et al. 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits , 2015, Oncotarget.
[15] C. Heeschen,et al. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. , 2015, Cell metabolism.
[16] Hye-Jin Park,et al. Autophagy sustains the survival of human pancreatic cancer PANC-1 cells under extreme nutrient deprivation conditions. , 2015, Biochemical and biophysical research communications.
[17] Anneleen Daemen,et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors , 2015, Proceedings of the National Academy of Sciences.
[18] R. Deberardinis,et al. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. , 2014, Cell reports.
[19] R. Kalluri,et al. Corrigendum: PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis , 2014, Nature Cell Biology.
[20] John M. Asara,et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.
[21] Gerald C. Chu,et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. , 2014, Cancer discovery.
[22] C. Kang,et al. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients with Pancreatic Cancer , 2014, The Journal of Nuclear Medicine.
[23] Amy Y. M. Au,et al. p53 status determines the role of autophagy in pancreatic tumour development , 2013, Nature.
[24] D. Klionsky,et al. Participation of mitochondrial fission during mitophagy , 2013, Cell cycle.
[25] P. Delvenne,et al. Myoferlin is a key regulator of EGFR activity in breast cancer. , 2013, Cancer research.
[26] Jun S. Song,et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.
[27] Bond-Smith Giles,et al. Only women with symptoms need to have their breast implants removed, says government , 2012 .
[28] Denis Mottet,et al. HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells , 2012, Cell Death and Differentiation.
[29] J. Martinou,et al. Dual role of mitofilin in mitochondrial membrane organization and protein biogenesis. , 2011, Developmental cell.
[30] R. Youle,et al. Coupling mitochondrial and cell division , 2011, Nature Cell Biology.
[31] P. Delvenne,et al. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. , 2011, Journal of proteome research.
[32] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[33] P. Spellman,et al. Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.
[34] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[35] F. Chantraine,et al. Thiamine Status in Humans and Content of Phosphorylated Thiamine Derivatives in Biopsies and Cultured Cells , 2010, PloS one.
[36] W. Sessa,et al. Myoferlin is critical for endocytosis in endothelial cells. , 2009, American journal of physiology. Cell physiology.
[37] Gregory Q. Wallace,et al. The Endocytic Recycling Protein EHD2 Interacts with Myoferlin to Regulate Myoblast Fusion* , 2008, Journal of Biological Chemistry.
[38] R. Slack,et al. The phosphorylation state of Drp1 determines cell fate , 2007, EMBO reports.
[39] J. Nunnari. The machines that divide and fuse mitochondria , 2007, Annual review of biochemistry.
[40] J. Martinou,et al. Mitochondria and cancer: is there a morphological connection? , 2006, Oncogene.
[41] D. Davis,et al. Normal myoblast fusion requires myoferlin , 2005, Development.
[42] D. Chan,et al. Emerging functions of mammalian mitochondrial fusion and fission. , 2005, Human molecular genetics.
[43] D. Chan,et al. Disruption of Fusion Results in Mitochondrial Heterogeneity and Dysfunction* , 2005, Journal of Biological Chemistry.
[44] John L. Humm,et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[45] N. Tamaki,et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[46] C. Hackenbrock. ULTRASTRUCTURAL BASES FOR METABOLICALLY LINKED MECHANICAL ACTIVITY IN MITOCHONDRIA , 1966, The Journal of cell biology.
[47] M. Protopopova,et al. Abstract PR01: IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities , 2017 .
[48] Edward F. Chang,et al. Abstract A65: IACS-10759: A novel OXPHOS inhibitor that selectively kills tumors with metabolic vulnerabilities , 2016 .
[49] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[50] Peter Dalgaard,et al. R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .
[51] Wolfgang Schima,et al. Pancreatic adenocarcinoma , 2006, European Radiology.
[52] H. Elsässer,et al. Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma , 1992, Virchows Archiv. B, Cell pathology including molecular pathology.
[53] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.